Although several phase III clinical trials have explored the synergistic potential of ICIs in conjunction with bevacizumab or tyrosine kinase inhibitors (TKIs) for the treatment of advanced HCC, only the combination of atezolizumab and bevacizumab had obtained approval from received Food and Drug Administration at that time.6 However, in China, no programmed cell death protein 1 (PD-1) inhibitor combined with anti-VEGF therapy had been approved for the treatment of advanced HCC at the onset of this trial. Here, PDCD1 is linked to hepatocellular carcinoma.